Teladoc Inc. (NYSE:TDOC) has been given an average recommendation of “Buy” by the thirteen ratings firms that are covering the firm. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $22.86.
TDOC has been the subject of several research analyst reports. FBR & Co lowered their price objective on shares of Teladoc from $36.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, July 20th. Piper Jaffray Cos. restated an “overweight” rating and set a $22.00 price objective (up from $20.00) on shares of Teladoc in a research report on Monday, July 11th. Zacks Investment Research upgraded shares of Teladoc from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Monday, July 25th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $24.00 price objective (down from $25.00) on shares of Teladoc in a research report on Friday, August 5th. Finally, Deutsche Bank AG lowered their price objective on shares of Teladoc from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, August 4th.
Teladoc (NYSE:TDOC) opened at 18.31 on Monday. The company’s 50-day moving average price is $18.30 and its 200 day moving average price is $14.25. Teladoc has a 52-week low of $9.08 and a 52-week high of $22.00. The firm’s market capitalization is $836.86 million.
Teladoc (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.01. Teladoc had a negative net margin of 60.88% and a negative return on equity of 33.97%. The business earned $26.50 million during the quarter, compared to the consensus estimate of $28.20 million. During the same period in the previous year, the business earned ($0.46) earnings per share. The company’s revenue was up 44.9% on a year-over-year basis. Equities analysts predict that Teladoc will post ($1.45) earnings per share for the current fiscal year.
In related news, CEO Jason N. Gorevic sold 5,000 shares of the business’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $15.45, for a total value of $77,250.00. Following the sale, the chief executive officer now owns 932,258 shares of the company’s stock, valued at $14,403,386.10. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director James K. Outland sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $18.00, for a total transaction of $180,000.00. Following the completion of the sale, the director now directly owns 49,089 shares in the company, valued at approximately $883,602. The disclosure for this sale can be found here. 5.94% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the company. Capital World Investors purchased a new stake in shares of Teladoc during the second quarter worth approximately $18,411,000. Sectoral Asset Management Inc. boosted its stake in shares of Teladoc by 50.1% in the second quarter. Sectoral Asset Management Inc. now owns 1,464,221 shares of the company’s stock worth $23,457,000 after buying an additional 488,688 shares during the period. EverPoint Asset Management LLC purchased a new stake in shares of Teladoc during the second quarter worth approximately $5,207,000. BlackRock Fund Advisors boosted its stake in shares of Teladoc by 138.0% in the second quarter. BlackRock Fund Advisors now owns 536,706 shares of the company’s stock worth $8,598,000 after buying an additional 311,232 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Teladoc by 27.1% in the second quarter. Vanguard Group Inc. now owns 1,352,814 shares of the company’s stock worth $21,671,000 after buying an additional 288,363 shares during the period. 40.45% of the stock is currently owned by institutional investors.
Teladoc, Inc, together with its subsidiaries, is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company operates through health services segment. Its solution connects its Members, with its over 3,000 board-certified physicians and behavioral health professionals who treat a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.